Azitra, Inc.
494.8M
$3.03M
-0.12
$-2.25
No price alerts set. Add an alert to get notified!
-0.12
0.00
$-2.25
-0.29%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
$1.93 | -1.48% | -0.06 | $1.15M | 0.00 |
|
INDP
Indaptus Therapeutics, Inc.
|
$1.68 | -4.83% | -0.17 | $2.86M | 0.00 |
|
JSPR
Jasper Therapeutics, Inc.
|
$1.22 | -0.41% | -0.22 | $19.67M | 0.15 |
|
LIPO
Lipella Pharmaceuticals Inc.
|
$0.15 | -11.76% | -0.13 | $693,126 | 0.18 |
|
ONCO
Onconetix, Inc.
|
$0.46 | -4.00% | -0.03 | $264,613 | 0.00 |
|
REVB
Revelation Biosciences, Inc.
|
$1.18 | -1.67% | -0.82 | $1.75M | 0.08 |
|
SCNI
Scinai Immunotherapeutics Ltd.
|
$0.71 | 0.37% | -0.14 | $930,754 | 0.30 |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
$0.84 | 29.23% | -0.70 | $4.92M | 0.00 |
|
SLXN
Silexion Therapeutics Ltd.
|
$1.22 | -15.55% | -0.32 | $681,571 | 0.18 |
|
SPRC
SciSparc Ltd.
|
$4.44 | -4.70% | -0.02 | $256,851 | -3.14 |
* Peer stocks are selected based on market capitalization and sector
$2.67
$0.10
$0.00
0.00%
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
